




>>Entry Name: Troglitazone, BAN, INN, USAN

Synonym(s): 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione, 9CI. Nosc. Romglizone. Ronglitazone. Rezulin. Romozin. CI 991. GR 92132X



CAS Registry Number: 97322-87-7

Related CAS Registry Numbers(s): 97323-06-3

Molecular Formula: C₂₄H₂₇NO₅S

Molecular Weight: 441.547

Accurate Mass: 441.160994

Percentage Composition: C 65.29%; H 6.16%; N 3.17%; O 18.12%; S 7.26%

Use/Importance: Antioxidant

Biological Use/Importance: Peroxisome proliferator activated receptor (PPAR- γ) agonist. Oral antihyperglycaemic agent.

Physical Description: Cryst. (C₆H₆/Me₂CO)

Development Status: Marketed drug (except UK). Launched and then withdrawn (1997) in the UK following reports of adverse hepatic effects

Melting Point: Mp 184-186°

Calculated Log P Data: Log P 5.57 (calc)

Other Data: Mixt. of 2 racemates

References:

- Eur. Pat.*, 1987, *Sankyo*, 207 581; *CA*, **106**, 119879r, (*synth, pharmacol*)
Fujiwara, T. *et al.*, *Diabetes*, 1988, **37**, 1549, (*pharmacol*)
Yoshioka, T. *et al.*, *J. Med. Chem.*, 1989, **32**, 421, (*synth, pmr, pharmacol*)
Fujiwara, T. *et al.*, *Metab., Clin. Exp.*, 1991, **40**, 1213; 1993, **42**, 75, (*pharmacol*)
Kellerer, M. *et al.*, *Diabetes*, 1994, **43**, 447, (*pharmacol*)
Ciaraldi, T.P. *et al.*, *Metab., Clin. Exp.*, 1995, **44**, 976, (*pharmacol*)
Inoue, I. *et al.*, *Biochem. Biophys. Res. Commun.*, 1997, **235**, 113-116, (*pharmacol*)
Lenhard, J.M. *et al.*, *Biochem. Pharmacol.*, 1997, **54**, 801-808, (*pharmacol*)
Spencer, C.M. *et al.*, *Drugs*, 1997, **54**, 89-101, (*rev*)
Vyas, K. *et al.*, *Acta Cryst. C*, 1999, **55**, 411-413, (*cryst struct*)
Plosker, G.L. *et al.*, *Drugs*, 1999, **57**, 409-438, (*rev*)
Martindale, The Extra Pharmacopoeia, 32nd edn., *Pharmaceutical Press*, 1999, 334